Bluefin Capital Management, LLC Gilead Sciences, Inc. Transaction History

Bluefin Capital Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 16, 2024	BUY	$73.27 - $83.09 $930,529 - $1.06 Million	12,700 New	12,700 $1.03 Million
Q4 2022 Feb 14, 2023	BUY	$62.32 - $89.47 $2.4 Million - $3.45 Million	38,568 Added 482.1%	46,568 $4 Million
Q3 2022 Nov 14, 2022	BUY	$59.54 - $68.01 $172,666 - $197,229	2,900 Added 56.86%	8,000 $494,000
Q2 2022 Aug 15, 2022	SELL	$57.72 - $65.01 $525,252 - $591,591	-9,100 Reduced 64.08%	5,100 $319,000
Q1 2022 May 16, 2022	BUY	$57.92 - $72.58 $86,880 - $108,870	1,500 Added 11.81%	14,200 $844,000
Q4 2021 Feb 14, 2022	SELL	$64.88 - $73.64 $2.95 Million - $3.35 Million	-45,460 Reduced 78.16%	12,700 $922,000
Q3 2021 Nov 15, 2021	BUY	$67.69 - $73.03 $1.23 Million - $1.33 Million	18,180 Added 45.47%	58,160 $4.06 Million
Q2 2021 Aug 16, 2021	BUY	$63.47 - $69.35 $1.04 Million - $1.14 Million	16,380 Added 69.41%	39,980 $2.75 Million
Q1 2021 May 17, 2021	BUY	$60.0 - $68.46 $1.2 Million - $1.37 Million	20,012 Added 557.75%	23,600 $1.53 Million
Q4 2020 Feb 10, 2021	SELL	$56.65 - $64.55 $91,376 - $104,119	-1,613 Reduced 31.01%	3,588 $209,000
Q3 2020 Nov 16, 2020	BUY	$62.1 - $78.08 $322,982 - $406,094	5,201 New	5,201 $329,000

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Bluefin Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Bluefin Capital Management, LLC with notifications on news.